Vis enkel innførsel

dc.contributor.authorBennett, Sean
dc.contributor.authorSøreide, Kjetil
dc.contributor.authorGholami, Sepideh
dc.contributor.authorPessaux, Patrick
dc.contributor.authorTeh, Catherine S.C.
dc.contributor.authorSegelov, Eva
dc.contributor.authorKennecke, Hagen Fritz
dc.contributor.authorPrenen, Hans
dc.contributor.authorMyrehaug, Sten D.
dc.contributor.authorCallegaro, Dario
dc.contributor.authorHallet, Julie
dc.date.accessioned2021-05-28T15:05:30Z
dc.date.available2021-05-28T15:05:30Z
dc.date.created2020-11-19T11:25:18Z
dc.date.issued2020
dc.PublishedCurrent Oncology. 2020, 27 (5), e501-e511.
dc.identifier.issn1198-0052
dc.identifier.urihttps://hdl.handle.net/11250/2756929
dc.description.abstractObjective: We aimed to review data about delaying strategies for the management of hepatobiliary cancers requiring surgery during the covid-19 pandemic. Background: Given the covid-19 pandemic, many jurisdictions, to spare resources, have limited access to operating rooms for elective surgical activity, including cancer, thus forcing deferral or cancellation of cancer surgeries. Surgery for hepatobiliary cancer is high-risk and particularly resource-intensive. Surgeons must critically appraise which patients will benefit most from surgery and which ones have other therapeutic options to delay surgery. Little guidance is currently available about potential delaying strategies for hepatobiliary cancers when surgery is not possible. Methods: An international multidisciplinary panel reviewed the available literature to summarize data relating to standard-of-care surgical management and possible mitigating strategies to be used as a bridge to surgery for colorectal liver metastases, hepatocellular carcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, and hilar cholangiocarcinoma. Results: Outcomes of surgery during the covid-19 pandemic are reviewed. Resource requirements are summarized, including logistics and adverse effects profiles for hepatectomy and delaying strategies using systemic, percutaneous and radiation ablative, and liver embolic therapies. For each cancer type, the long-term oncologic outcomes of hepatectomy and the clinical tools that can be used to prognosticate for individual patients are detailed. Conclusions: There are a variety of delaying strategies to consider if availability of operating rooms decreases. This review summarizes available data to provide guidance about possible delaying strategies depending on patient, resource, institution, and systems factors. Multidisciplinary team discussions should be leveraged to consider patient- and tumour-specific information for each individual case.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleStrategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemicen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2020 Multimed Inc.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3747/co.27.6785
dc.identifier.cristin1849747
dc.source.journalCurrent Oncologyen_US
dc.source.4027
dc.source.145
dc.source.pagenumber501-511en_US
dc.identifier.citationCurrent Oncology. 2020, 27 (5), 501-511en_US
dc.source.volume27en_US
dc.source.issue5en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal